STOCK TITAN

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
YS Biopharma announces unaudited financial results for the first nine months of fiscal year 2024, highlighting revenue decline due to supply chain disruptions but increased gross margin. Positive clinical trial results for next-generation rabies vaccine and approval for immunotherapeutic vaccine in the Philippines signal growth opportunities. The Company focuses on operational enhancements, cost controls, and future product commercialization to drive shareholder value.
YS Biopharma annuncia i risultati finanziari non auditati per i primi nove mesi dell'anno fiscale 2024, evidenziando una diminuzione del fatturato a causa di interruzioni nella catena di approvvigionamento, ma con un aumento del margine lordo. Risultati positivi degli studi clinici per il vaccino antirabbico di nuova generazione e l'approvazione del vaccino immunoterapeutico nelle Filippine indicano opportunità di crescita. La società si concentra su miglioramenti operativi, controllo dei costi e commercializzazione dei prodotti futuri per aumentare il valore per gli azionisti.
YS Biopharma anuncia los resultados financieros no auditados para los primeros nueve meses del año fiscal 2024, destacando una disminución en los ingresos debido a interrupciones en la cadena de suministro pero con un aumento en el margen bruto. Los resultados positivos de los ensayos clínicos para la vacuna contra la rabia de próxima generación y la aprobación de la vacuna inmunoterapéutica en Filipinas señalan oportunidades de crecimiento. La compañía se enfoca en mejoras operativas, control de costos y la comercialización de productos futuros para impulsar el valor para los accionistas.
YS Biopharma는 2024 회계년도 첫 9개월의 감사되지 않은 재무 결과를 발표했습니다. 이 결과에는 공급망 차질로 인한 매출 감소와 더불어 총마진이 증가했다는 점이 강조되었습니다. 차세대 광견병 백신에 대한 긍정적인 임상 시험 결과와 필리핀에서의 면역 치료 백신 승인은 성장 기회를 나타냅니다. 회사는 운영 개선, 비용 통제 및 미래 제품 상용화에 집중하여 주주 가치를 증대시키고 있습니다.
YS Biopharma annonce les résultats financiers non audités pour les neuf premiers mois de l'exercice fiscal 2024, soulignant une baisse des revenus due à des perturbations de la chaîne d'approvisionnement mais une augmentation de la marge brute. Les résultats positifs des essais cliniques pour le vaccin antirabique de nouvelle génération et l'approbation du vaccin immunothérapeutique aux Philippines signalent des opportunités de croissance. La société se concentre sur l'amélioration opérationnelle, le contrôle des coûts et la commercialisation de futurs produits pour augmenter la valeur pour les actionnaires.
YS Biopharma gibt die ungeprüften Finanzergebnisse für die ersten neun Monate des Geschäftsjahres 2024 bekannt, wobei ein Rückgang der Einnahmen aufgrund von Störungen in der Lieferkette, aber eine Erhöhung der Bruttomarge hervorgehoben wird. Positive klinische Studienergebnisse für den Impfstoff der nächsten Generation gegen Tollwut und die Zulassung des immuntherapeutischen Impfstoffs auf den Philippinen signalisieren Wachstumschancen. Das Unternehmen konzentriert sich auf betriebliche Verbesserungen, Kostenkontrolle und die Kommerzialisierung zukünftiger Produkte, um den Aktionärswert zu steigern.
Positive
  • Revenue decline of 24.6% in fiscal 2024 compared to 2023 due to supply chain disruptions.
  • Gross profit of RMB 351.7 million with an 80.3% margin, a slight increase from fiscal 2023.
  • Selling and marketing expenses rise to RMB 229.2 million, driven by promotional efforts for YSJA rabies vaccine.
  • General and administrative expenses increase to RMB 142.8 million, mainly due to inventory impairment provisions.
  • Research and development expenses rise to RMB 244.7 million, driven by testing and clinical trial fees for rabies and Hepatitis B vaccines.
  • Net loss of RMB 252.3 million in fiscal 2024 compared to RMB 64.2 million in 2023.
  • Cash position decreases to RMB 222.6 million as of December 31, 2023, from RMB 370.4 million in March 2023.
Negative
  • None.

Insights

YS Biopharma's financial results reveal a noteworthy 24.6%> drop in revenues compared to the previous year, attributed to supply chain disruptions. The increase in gross profit margin to 80.3%> demonstrates effective pricing strategies and cost control. Investors should be alert to the $35.6 million> net loss, a substantial increase from the prior year, potentially reflecting increased R&D expenses and the challenging operational context. The balance sheet shows a decrease in cash reserves, signaling a need to monitor liquidity closely.

Significant advancements in YS Biopharma's clinical pipeline, particularly the PIKA Rabies Vaccine's positive interim Phase III results, might inform investor expectations for future revenue streams. The clinical approval of YS-HBV-002 by the Philippine FDA represents progress towards addressing chronic hepatitis B, potentially expanding the company's therapeutic footprint. Such pipeline developments are critical in evaluating the firm's long-term potential, despite current financial pressures.

While current financials show strain, YS Biopharma's maintained market leadership in rabies vaccines in China and the successful commercialization of YSJATM signal positive market uptake and brand strength. The sales to over 60%> of CDC customers in China since October 2020 suggest a strong distribution network and market penetration, important levers for future revenue growth as supply chain issues are resolved.

GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first nine months of the fiscal year ended March 31, 2024.

Dr. David Shao, Director, President, and CEO of the Company, commented, "During the first nine months of fiscal year 2024, our topline continued to be impacted by the lingering effects of a finished product inventory shortage caused by the supply chain disruptions at our YSJA rabies vaccine manufacturing facilities. Importantly, in recent months, our operational enhancements have normalized vaccine production and improved our inventory situation. As a top rabies vaccine producer in China, we maintained our leadership position in the marketplace, with an estimated double-digit year-over-year growth in product sales during the fourth quarter of fiscal 2024. We also made steady progress on the pipeline front, with positive interim results from the ongoing Phase III clinical trial of our next-generation PIKA rabies vaccine, and our YS-HBV-002 immunotherapeutic vaccine has been granted clinical trial approval by the Philippine Food and Drug Administration."

Dr. David Shao continued, "At the corporate level, since late 2023 we have embarked on a comprehensive series of initiatives aimed at fortifying our foundation for future growth. These include restructuring the Board of Directors and senior management team, as well as streamlining organizational reporting lines and decision-making processes. Additionally, we've implemented measures to enhance internal controls and governance. Starting in March 2024, we took further steps forward, including prioritizing our preclinical and clinical pipeline and optimizing human resources across all our subsidiaries in the U.S., China, and Singapore. We also implemented more effective cost controls in our manufacturing, sales, marketing, and general administrative functions. These initiatives are ongoing and will remain a focus through the end of fiscal 2025. We are confident these efforts will serve as pillars for our future growth. Looking ahead, we will continue to advance our product portfolio towards commercialization, focus on operational efficiencies, and leverage our refined inventory strategy and robust sales network to build sustainable shareholder value."

Ms. Brenda Wu, CFO of the Company, added, "For the first nine months of our fiscal 2024, we recorded revenues of RMB438.1 million (US$61.9 million), primarily due to the lingering effects of supply chain disruptions affecting raw materials supply chains, manufacturing operations, and production output at our YSJA rabies vaccine production facilities. We recorded gross profit of RMB351.7 million (US$49.7 million) and expanded our gross margin by 3 percentage points to 80.3%. Our cash totaled RMB222.6 million (US$31.4 million) as of December 31, 2023. We remain committed to driving long-term shareholder value through strategic business enhancements and by capitalizing on emerging growth opportunities."

Business Updates

YSJATM Rabies Vaccine

YS Biopharma's marketed vaccine product, YSJATM rabies vaccine, was the first aluminum-free lyophilized rabies vaccine launched in China. Since the Company commenced production at its current GMP-compliant facilities in February 2020, and commercialization of the product in late 2020, market intake of the Company's YSJA rabies vaccine has been consistent and strong. As of December 31, 2023, YS Biopharma maintained its leadership position as one of the top rabies vaccine producers in China, having sold more than 25.6 million doses of YSJATM rabies vaccines to approximately 1,746 Chinese Center(s) for Disease Control and Prevention ("CDC") customers, which is over 60% of CDC customers in China since October 2020.

Clinical Pipeline

YS Biopharma continues to prioritize and advance its portfolio of innovative product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA YS-ON-001, and PIKA YS-HBV-002.

PIKA Rabies Vaccine

  • On April 9, 2024, the Company announced positive interim results from the ongoing Phase III clinical trial of its next-generation PIKA Rabies Vaccine. The interim results indicate the PIKA Rabies Vaccine has met the primary endpoints of the trial and has the potential to achieve best-in-class accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens.

PIKA YS-ON-001

  • PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. The Company has completed the Phase I clinical trial of PIKA YS-ON-001 in China.

PIKA YS-HBV-002

  • On April 18, 2024, the Company announced that its YS-HBV-002, the second generation of immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus infection, was granted clinical trial approval by the Philippine Food and Drug Administration. In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines, which is expected to begin in June 2024.

First Nine Months of Fiscal 2024 Financial Results

Total Revenues

Total revenues were RMB438.1 million (US$61.9 million) in the first nine months of fiscal 2024, compared to RMB581.2 million in the comparable period of fiscal 2023, a decrease of 24.6%. This was primarily due to the lingering effects of supply-chain disruptions affecting the Company's manufacturing operations and production, which reduced batch approvals and doses available for sale; offset by the increases in product price by approximately RMB3.0 per dose.

Gross Profit

Gross profit was RMB351.7 million (US$49.7 million), an 80.3% gross margin, compared to RMB449.0 million, or a 77.3% gross margin, in the comparable period of fiscal 2023.

Selling and Marketing Expenses

Selling and marketing expenses in the first nine months of fiscal 2024 were RMB229.2 million (US$32.4 million), compared to RMB224.5 million in the comparable period of fiscal 2023. This was primarily attributable to an increase in promotional and marketing services fees as the Company continued to promote its YSJA rabies vaccine.

General and Administrative Expenses

General and administrative expenses in the first nine months of fiscal 2024 were RMB142.8 million (US$20.2 million), compared to RMB68.6 million in the comparable period of fiscal 2023. This change was primarily attributable to increases in provisions for inventory impairment and provisions for trade receivables.

Research and Development Expenses

Research and development expenses were RMB244.7 million (US$34.5 million) in the first nine months of fiscal 2024, compared to RMB221.8 million in the comparable period of fiscal 2023. The change was primarily driven by the increase in testing and clinical trial fees associated with the Company's PIKA rabies vaccine and Hepatitis B vaccines.

Net Loss

Net loss for the first nine months of fiscal 2024 was RMB252.3 million (US$35.6 million), compared with RMB64.2 million in the comparable period of fiscal 2023.

Balance Sheet

As of December 31, 2023, the Company had cash of RMB222.6 million (US$31.4 million), compared with RMB370.4 million as of March 31, 2023.

Conference Call Information

The Company's management will hold an earnings conference call on Friday, April 19, 2024 at 8:00 A.M. Eastern Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free:

1-888-346-8982


International:

1-412-902-4272


Mainland China Toll Free:

4001-201203


Canada Toll Free:

1-855-669-9657


Hong Kong:

852-301-84992


The replay will be accessible through April 26, 2024 by dialing the following numbers:

United States Toll Free:

1-877-344-7529


International:

1-412-317-0088


Canada Toll Free:

855-669-9658


Access Code:

2468327


A live and archived webcast of the conference call will also be available at the Company's investor relations website at https://investor.ysbiopharma.com/.

About YS Group

YS Group is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.0827 to US$1.00, the exchange rate set forth in the central parity rate release of the People's Bank of China on December 31, 2023.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma's ability to source and retain talent, and the cash position of YS Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance.

YS Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Post-effective Amendment No. 2 to the Company's Registration Statement on Form F-1 filed with the SEC on January 23, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact

Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com 

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com 

 

 

YS Biopharma Co., Ltd.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(All amounts in thousands, except for share and per share data)  






As of
March 31,



As of December 31,




2023



2023



2023




RMB



RMB



US$












ASSETS










Current assets










Cash



370,108




222,614




31,431


Restricted cash



262




-




-


Accounts receivable, net



463,052




403,122




56,916


Advance to suppliers, net



6,763




12,086




1,706


Inventories, net



185,381




178,659




25,225


Prepaid expenses and other current assets



10,413




10,128




1,430


Total current assets



1,035,979




826,609




116,708















Non-current assets













Property, plant and equipment, net



571,756




560,405




79,123


Operating lease right-of-use assets, net



11,132




8,426




1,190


Deferred tax assets, net



1,906




10,165




1,435


Intangible assets, net



78,057




72,942




10,299


Other assets, non-current



20,924




31,884




4,502


Total non-current assets



683,775




683,822




96,549















Total assets



1,719,754




1,510,431




213,257















LIABILITIES AND SHAREHOLDERS' EQUITY













Current liabilities













Bank loans and other borrowings - current



193,737




423,880




59,847


Accounts payable



80,439




77,541




10,948


Accrued expenses and other liabilities



377,537




374,102




52,820


Operating lease liabilities - current



4,754




5,102




720


Deferred government grants - current



2,296




2,226




314


Total current liabilities



658,763




882,851




124,649















Non-current liabilities













Bank loans and other borrowings – non-current



293,791




125,067




17,658


Operating lease liabilities - non-current



6,349




4,042




571


Deferred government grants - non-current



23,607




21,627




3,053


Warrants liability



8,792




2,334




330


Total non-current liabilities



332,539




153,070




21,612















Total liabilities



991,302




1,035,921




146,261















Shareholders' equity













Ordinary shares



12




12




2


Additional paid-in capital



2,656,891




2,656,891




375,124


Accumulated deficit



(1,874,039)




(2,126,332)




(300,215)


Accumulated other comprehensive loss



(54,412)




(56,061)




(7,915)


Total shareholders' equity



728,452




474,510




66,996















Total liabilities and shareholders' equity



1,719,754




1,510,431




213,257


 

 

 

YS Biopharma Co., Ltd.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(All amounts in thousands, except for share and per share data)






For the nine months ended
December 31,




2022



2023



2023




RMB



RMB



US$












Revenues



581,184




438,069




61,851


Cost of revenues



132,226




86,374




12,195


Gross profit



448,958




351,695




49,656















Operating expenses:













    Selling and marketing



224,467




229,180




32,358


    General and administrative



68,647




142,775




20,158


    Research and development



221,798




244,665




34,544


Total operating expenses



514,912




616,620




87,060















Loss from operations



(65,954)




(264,925)




(37,404)















Other income (expenses):













     Late fees for social security insurance



(565)




(560)




(79)


     Government grants



25,497




19,141




2,703


     Interest income



917




1,965




277


     Interest expense



(22,661)




(23,072)




(3,258)


     Fair value changes of warrant liability



-




6,628




936


     Other income, net



287




270




38


Total other expense, net



3,475




4,372




617















Loss before income taxes



(62,479)




(260,553)




(36,787)


Income tax (benefit) expense 



(1,731)




8,260




1,166















Net loss



(64,210)




(252,293)




(35,622)


      Accretion to redemption value of convertible redeemable preferred
         shares



(108,296)




-




-















Net loss attributable to YS Group



(172,506)




(252,293)




(35,622)















Net loss



(64,210)




(252,293)




(35,622)


     Other comprehensive loss: foreign currency translation adjustment



(144,542)




(1,649)




(233)


Total comprehensive loss



(208,752)




(253,942)




(35,855)















Weighted average number of ordinary shares outstanding:













     – Basic and Diluted



61,785,466




93,058,197




NA


Loss per share:













     – Basic and Diluted



(1.04)




(2.71)




NA


 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-unaudited-financial-results-for-the-first-nine-months-of-fiscal-year-2024-302121952.html

SOURCE YS Biopharma Co., Ltd.

FAQ

What were YS Biopharma's total revenues in the first nine months of fiscal 2024?

Total revenues were RMB438.1 million (US$61.9 million) in the first nine months of fiscal 2024.

What was YS Biopharma's gross profit margin in the first nine months of fiscal 2024?

Gross profit was RMB351.7 million (US$49.7 million) with an 80.3% margin.

What were the selling and marketing expenses for YS Biopharma in the first nine months of fiscal 2024?

Selling and marketing expenses were RMB229.2 million (US$32.4 million) in the first nine months of fiscal 2024.

What was YS Biopharma's net loss for the first nine months of fiscal 2024?

Net loss for the first nine months of fiscal 2024 was RMB252.3 million (US$35.6 million).

What was YS Biopharma's cash position as of December 31, 2023?

The Company had cash of RMB222.6 million (US$31.4 million) as of December 31, 2023.

What positive clinical trial results did YS Biopharma announce recently?

YS Biopharma announced positive interim results from the ongoing Phase III clinical trial of its next-generation PIKA Rabies Vaccine.

Which immunotherapeutic vaccine of YS Biopharma was granted clinical trial approval by the Philippine Food and Drug Administration?

YS Biopharma's YS-HBV-002 immunotherapeutic vaccine was granted clinical trial approval by the Philippine Food and Drug Administration.

YS Biopharma Co., Ltd. Ordinary Shares

NASDAQ:YS

YS Rankings

YS Latest News

YS Stock Data

192.09M
188.33M
81.43%
2.85%
0.02%
Biotechnology
Healthcare
Link
United States of America
Beijing